文献速递垂体与肾上腺疾病

散发性嗜铬细胞瘤和副神经节瘤患者的复发疾病

Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项多中心回顾性研究纳入1127例嗜铬细胞瘤或副神经节瘤(PPGL)患者,比较散发性与遗传性PPGL的复发率。散发性PPGL复发率为14.7%,低于激活假缺氧通路的致病性变异患者(47.5%),但与激活激酶通路变异患者(14.9%)相似。多变量回归显示去甲肾上腺素/多巴胺能表型、较大肿瘤尺寸和肾上腺外位置是散发性PPGL复发的独立预测因素。

要点

  • 散发性PPGL复发率为14.7%,低于假缺氧通路变异患者(47.5%),与激酶通路变异患者(14.9%)相似。
  • 散发性复发性PPGL中,29.1%和17.7%分别在首次诊断后至少10年和15年确诊。
  • 去甲肾上腺素/多巴胺能表型(HR 2.73)、较大尺寸(HR 1.82)和肾上腺外位置(HR 1.79)是散发性PPGL复发的独立预测因素。

核心结论

  • 散发性PPGL患者需要长期随访,依据是14.7%的复发率,包括首次诊断后10年以上的复发。
  • 随访性质可根据肿瘤大小、位置和生化表型进行个体化。

研究设计与样本

  • 多中心研究,纳入1127例PPGL患者的回顾性数据。
  • 散发性PPGL定义为基因检测结果阴性。
  • 收集性别、原发肿瘤诊断年龄、位置、大小、儿茶酚胺表型、基因检测结果及后续复发和/或转移性疾病信息。

主要发现

  • 散发性PPGL患者复发率为14.7%,低于激活假缺氧通路的致病性变异患者(47.5%)(P < 0.001),与激活激酶通路的变异患者(14.9%)相似。
  • 散发性复发性PPGL患者中,29.1%在首次诊断后至少10年确诊,17.7%在至少15年确诊。
  • 多变量回归分析显示,去甲肾上腺素/多巴胺能表型(HR 2.73;95%CI 1.553-4.802;P < 0.001)、较大尺寸(HR 1.82;95%CI 1.113-2.962;P = 0.017)和肾上腺外位置(HR 1.79;95%CI 1.002-3.187;P = 0.049)是散发性PPGL复发的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Long-term follow-up has been recommended for patients with pheochromocytoma or paraganglioma (PPGL) due to potential for recurrent disease. However, the need to follow patients with sporadic PPGL has recently become controversial. OBJECTIVE: To investigate the prevalence of recurrence among patients with sporadic compared with hereditary PPGL and to identify predictors of recurrence for sporadic disease. METHODS: This multicenter study included retrospective data from 1127 patients with PPGL. In addition to sex and age at primary tumor diagnosis, clinical information included location, size, and catecholamine phenotype of primary tumors, genetic test results, and subsequent development of recurrent and/or metastatic disease. Patients with sporadic PPGL were defined as those with negative genetic test results. RESULTS: Prevalence of recurrence among patients with sporadic PPGL (14.7%) was lower (P < 0.001) than for patients with pathogenic variants that activate pseudohypoxia pathways (47.5%), but similar to those with variants that activate kinase pathways (14.9%). Among patients with sporadic recurrent PPGL, 29.1% and 17.7% were respectively diagnosed at least 10 and 15 years after first diagnosis. Multivariable regression analysis showed that a noradrenergic/dopaminergic phenotype (HR 2.73; 95% CI, 1.553-4.802; P < 0.001), larger size (HR 1.82; 95% CI, 1.113-2.962; P = 0.017) and extra-adrenal location (HR 1.79; 95% CI, 1.002-3.187; P = 0.049) of primary tumors were independent predictors of recurrence in sporadic PPGL. CONCLUSION: Patients with sporadic PPGL require long-term follow-up, as supported by the 14.7% prevalence of recurrent disease, including recurrences at more than 10 years after first diagnosis. The nature of follow-up could be individualized according to tumor size, location, and biochemical phenotype.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Li M, Prodanov T, Meuter L, et al. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2023. PMID: 36190922. doi:10.1210/clinem/dgac563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。